Aligos Total Assets from 2010 to 2024

ALGS Stock

USD 25.51 2.52 10.96%

Aligos Therapeutics Total Assets yearly trend continues to be comparatively stable with very little volatility. Total Assets are likely to outpace its year average in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2010-12-31

Previous Quarter

151.5 M

Current Value

193.1 M

Quarterly Volatility

51.5 M

Credit Downgrade

Yuan Drop

Covid

Check Aligos Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aligos Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 834.8 K, Net Interest Income of 1.3 M or Interest Income of 1 M, as well as many indicators such as Price To Sales Ratio of 25.26, Dividend Yield of 0.0 or PTB Ratio of 4.71. Aligos financial statements analysis is a perfect complement when working with Aligos Therapeutics Valuation or Volatility modules.

Check out the analysis of Aligos Therapeutics Correlation against competitors.

For more information on how to buy Aligos Stock please use our How to Invest in Aligos Therapeutics guide.

Latest Aligos Therapeutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of Aligos Therapeutics over the last few years. Total assets refers to the total amount of Aligos Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Aligos Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Aligos Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aligos Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 151.53 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Aligos Total Assets Regression Statistics

	Arithmetic Mean	140,537,736
	Geometric Mean	133,558,658
	Coefficient Of Variation	36.68
	Mean Deviation	39,368,083
	Median	107,731,000
	Standard Deviation	51,547,716
	Sample Variance	2657.2T
	Range	157.6M
	R-Value	0.66
	Mean Square Error	1631.7T
	R-Squared	0.43
	Significance	0.01
	Slope	7,556,587
	Total Sum of Squares	37200.3T

Aligos Total Assets History

	2024	193.1 M
	2023	151.5 M
	2022	146.7 M
	2021	235.4 M
	2020	265.3 M
	2019	146.5 M

Other Fundumenentals of Aligos Therapeutics

Intangibles To Total Assets

Aligos Therapeutics Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment	Capital Surpluse
Total Assets		0.91	0.9	0.54	-0.97	-0.6	0.25	-0.81	-0.61	0.91	1.0	0.98	0.76	0.47	-0.25	0.4
Total Stockholder Equity	0.91		1.0	0.48	-0.93	-0.7	0.21	-0.79	-0.88	1.0	0.93	0.89	0.84	0.5	-0.42	0.55
Net Tangible Assets	0.9	1.0		0.44	-0.93	-0.73	0.18	-0.81	-0.89	1.0	0.92	0.88	0.86	0.56	-0.45	0.6
Current Deferred Revenue	0.54	0.48	0.44		-0.43	-0.16	0.63	-0.16	-0.23	0.48	0.52	0.47	0.43	-0.05	0.08	0.0
Net Debt	-0.97	-0.93	-0.93	-0.43		0.73	-0.2	0.9	0.68	-0.93	-0.98	-0.96	-0.86	-0.65	0.41	-0.57
Retained Earnings	-0.6	-0.7	-0.73	-0.16	0.73		-0.38	0.9	0.71	-0.7	-0.62	-0.52	-0.94	-0.86	0.9	-0.95
Accounts Payable	0.25	0.21	0.18	0.63	-0.2	-0.38		-0.15	-0.16	0.21	0.24	0.17	0.41	0.04	-0.43	0.2
Short Term Investments	-0.81	-0.79	-0.81	-0.16	0.9	0.9	-0.15		0.64	-0.79	-0.81	-0.75	-0.9	-0.84	0.65	-0.82
Total Liab	-0.61	-0.88	-0.89	-0.23	0.68	0.71	-0.16	0.64		-0.88	-0.66	-0.59	-0.76	-0.46	0.59	-0.65
Net Invested Capital	0.91	1.0	1.0	0.48	-0.93	-0.7	0.21	-0.79	-0.88		0.93	0.89	0.84	0.5	-0.42	0.55
Total Current Assets	1.0	0.93	0.92	0.52	-0.98	-0.62	0.24	-0.81	-0.66	0.93		0.99	0.78	0.49	-0.29	0.42
Net Working Capital	0.98	0.89	0.88	0.47	-0.96	-0.52	0.17	-0.75	-0.59	0.89	0.99		0.69	0.43	-0.19	0.31
Short Term Debt	0.76	0.84	0.86	0.43	-0.86	-0.94	0.41	-0.9	-0.76	0.84	0.78	0.69		0.8	-0.74	0.86
Common Stock	0.47	0.5	0.56	-0.05	-0.65	-0.86	0.04	-0.84	-0.46	0.5	0.49	0.43	0.8		-0.76	0.88
Property Plant Equipment	-0.25	-0.42	-0.45	0.08	0.41	0.9	-0.43	0.65	0.59	-0.42	-0.29	-0.19	-0.74	-0.76		-0.89
Capital Surpluse	0.4	0.55	0.6	0.0	-0.57	-0.95	0.2	-0.82	-0.65	0.55	0.42	0.31	0.86	0.88	-0.89

Click cells to compare fundamentals

About Aligos Therapeutics Financial Statements

Aligos Therapeutics shareholders use historical fundamental indicators, such as Total Assets, to determine how well the company is positioned to perform in the future. Although Aligos Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Aligos Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Aligos Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Total Assets	151.5 M	193.1 M
Intangibles To Total Assets	(0.01)	(0.02)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Aligos Stock Analysis

When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC